Barclays upgraded Relay Therapeutics to Overweight from Equal Weight with an unchanged price target of $15. The analyst sees an attractive catalyst path in the second half of 2024, including high-impact data update in breast cancer. It sees a positive positive risk /reward into the data and an attractive valuation at current share levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics price target lowered to $25 from $33 at Oppenheimer
- Relay Therapeutics reports Q1 EPS (62c), consensus (71c)
- Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
- Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
- Relay Therapeutics to Participate in Upcoming Investor Conferences